Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“Wow! It’s Big news on Friday.
F.D.A. Grants Early Access to Promising Drug for Pancreatic Cancer
Patients with one of the deadliest cancers have been pleading for an unapproved treatment that may prolong their lives.
Looking forward to American Society of Clinical Oncology (ASCO) for the data.
Other articles featuring Vivek Subbiah.